

## Søknadsinformasjon

---

<b>Utlysning</b>	Nordic Cancer Union Research Grant, 2014
<b>Søknad</b>	Association between gene variation and the response to chemotherapy for testicular cancer - clinical outcomes and adverse effec
<b>Søknadsid</b>	154987
<b>Innsendt av</b>	Tom Grotmol

## Oppgave: Progress report

---

<b>Tilordnet</b>	Tom Grotmol
<b>Status</b>	Arkivert
<b>Opprettet</b>	11.04.2017

## RAPPORT

---

### **Briefly describe the project in a language understandable to non-scientists**

Testicular cancer (TC) is the most common cancer in young men. Following the introduction of cisplatin-based therapies in the late 1970s, relative survival reached 95%. Given the good prognosis of TC, there is an increased attention on how to resolve cisplatin issues, such as drug resistance, and undesirable side effects, e.g., toxicities and increased risk of the metabolic syndrome and cardiovascular disease on a long-term.

The overall aim is to gain novel insight in the genetics underlying the response to chemotherapy by linkage of the genetic and clinical data of 1200 Norwegian and Swedish men and performing genetic association studies. We will analyze both the clinical response to chemotherapy and its long-term adverse effects.

The ultimate goal is to contribute to develop a more individualized chemotherapy to increase the survival for patients with a poor prognosis, and to reduce the treatment intensity for those with a good prognosis to minimize undesirable long-term effects.

### **Summarize the major findings of the project**

The research group was established during the first quarter of 2015 with a group meeting in Oslo and a subsequent telephone conference. The first task was to acquire an overview of how many patients do have data both in the genetic association study (GENETEC) and clinical data in SWENOTECA, including the number of seminoma and non-seminoma distributed diagnosis, in both countries.

During the second quarter of 2015 it was established through linkage of the two databases, that for Sweden, 913 of the 1187 patients in GENETEC were also covered in SWENOTECA, i.e., a 77 % overlap, a fraction that we are satisfied with.

The Norwegian material in GENETEC consists of about 900 testicular cancer patients (diagnosed 1990-2008). About 45% of these patients were treated at the Norwegian Radium Hospital, which was not part of SWENOTECA in the current period. The clinical data on these patients are therefore missing in the SWENOTECA database. It has been an important aim to include also these data from the hospital journals in the Radium Hospital (now part of the Oslo University Hospital, OUS). This process was started in the third quarter of 2015. The process for acquiring access to the OUS data is time consuming. According to the legislation, the first step is to apply for ethical approval from OUS. The Regional Committee for Medical Ethics had already approved the overall project.

When OUS approval was granted, the next step was to decide how to find a qualified and trustworthy person to collect the necessary information from the hospital records. After negotiating with the head of the Dept of Oncology at the OUS on how to proceed with the data acquisition process, an agreement was reached in 2016 as to how a project team member (physician at St. Olavs hospital in Trondheim) could collect clinical data from medical records at OUS.

This collection of medical data started last year and has continued during the first months of 2017. This project is unfortunately still not finished, but there are reasons to believe that the medical data will be complete before the summer this year.

We regret that we have not been able to advance further, but it is due to routines for achieving these kind of data in Norway. As soon as data have been acquired, we will proceed according to the protocol.

### **Describe how the project has increased our knowledge of the prevention, cause and/or cure for cancer**

No results are available as yet.

### **Outline how Nordic cooperation has added value to this project**

This project takes advantage of combining data on testicular cancer (TC) from Norway and Sweden. The Swedish Norwegian Testicular Cancer Group (SWENOTECA), comprising all patients in Sweden and the vast majority of those in Norway, provides clinical data which will be linked with genetic data on the same cases from GENETEC (GENetic analysis of TESTicular Cancer), which is a Norwegian-Swedish project devoted to population-based genetic association studies.

This enables us to conduct a study based on two high quality Norwegian-Swedish study groups/databases, SWENOTECA and GENETEC, which have both proven scientifically very valuable in their own right, respectively on clinical and genetic aspects of TC. In a wider perspective, the project takes joint advantage of the complete cancer registration in the Nordic countries. The large study population acquired by combining the two countries provides an excellent power to detect risk alleles.

### **Brief overview of expenditures for last year 1 vedlegg (expenditures for 2016.pdf)**

## Brief overview of expenditures for 2016

Last year, 24 907 NOK (ca 2700 EUR) was spent on travel expenses for group meetings and for travels in connection with data acquisition from the medical records at Oslo University Hospital. See below for documentation (row 10 'Reiseutgifter').

Copy of NCU pr. 26.04.2017.pdf - Adobe Reader

**KOSTNADER FOR PROSJEKT**  
**"TESTIS-PROSJEKT V/NCU" PR. 26.04.2017**

NCU - prosjekt 33121

	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
Tildeling fra NCU	-278 582,12	-1 186 080,00									
Innbetalt fra karolinia instituttet				-546 480,00	-180 000,00						
Registrerte jernkostnader A. Sløeg				98 658,53							
Overtid B. Mortensen				8 091,29							
Reiseutgifter			19 890,00			2 150,00	7 819,00		15 859,52	24 907,44	
Eppendorf					8 196,00						
Fisher Scientific AS					2 704,00						
Universitetet for miljø- og biovitenskap					1 047 500,00			145 237,50			
Vara						3 188,00					
MUGE										400 000,00	1 624,52
Biooridita										1 031,00	
Bio-Rad laborories									8 776,00		
Høgskolen i Oslo									5 737,50		
Life Technologies									16 589,75		
DHL											1 847,18
Clagen										30 336,61	
Marvik										10 637,50	
Andre kostnader	102 218,46	83 441,04	621 283,73	31 025,75	11 788,44	3 900,00	-47 788,45	1 382,00	6 150,00	9 815,41	
Overført gjenværende midler stipendiat											
Drukk pr. 26.04.2017	-175 703,66	-1 102 638,96	641 173,73	-411 654,43	890 188,44	9 238,00	-261 909,45	-537 329,63	53 086,77	476 727,96	3 471,70

11,69 x 8,27 in